TABLE 1

Objective response comparison for brentuximab vedotin and ado-trastuzumab emtansine with their respective parent nonconjugated monoclonal antibody

Antibodies can be empowered by chemically conjugating to a potent small-molecule drug. ADCs may enhance the antitumor activity compared with that of the unconjugated antibodies. Both brentuximab vedotin and ado-trastuzumab emtansine have demonstrated remarkable increases in objective response rate over their respective parent unconjugated antibodies in clinical trials (Younes et al., 2012; Forero-Torres et al., 2009; Pro et al., 2012; Baselga et al., 2005; Cobleigh et al., 1999; Kovtun et al., 2010; Vogel et al., 2002).